Syneos Health Stock Price, News & Analysis

Syneos Health (Nasdaq:SYNH) has entered a strategic partnership with Fosun Pharma USA to support the launch of Serplulimab, a novel anti-PD-1 antibody targeting extensive stage small cell lung cancer (ES-SCLC) in the U.S. This collaboration allows Syneos to provide comprehensive commercial support through its Syneos One team, enhancing Fosun's innovative medicine presence. Serplulimab is expected to be the first anti-PD-1 monoclonal antibody for first-line SCLC treatment, with the partnership aiming to optimize product development and market access.

Syneos Health (Nasdaq: SYNH) announced a transition in its executive leadership, with Jason Meggs resigning as CFO effective March 31, 2023. The company is currently searching for a successor while Mr. Meggs will provide consulting support through the end of 2023. Despite this change, Syneos Health has reaffirmed its 2022 revenue guidance, based on preliminary results from the year ending December 31, 2022. The leadership transition is not related to any disagreements concerning financial statements.

Syneos Health (Nasdaq:SYNH) announced that CEO Michelle Keefe will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. EST. The company will not conduct investor meetings during the event. Investors can access a live webcast, presentation materials, and archived replays on the company's Investor Relations website.

Syneos Health, a fully integrated biopharmaceutical solutions organization, aims to accelerate customer success through innovative product development and a deep understanding of market dynamics.

Syneos Health (Nasdaq:SYNH) has extended its strategic partnership with Medable to enhance decentralized clinical trial solutions. This collaboration aims to improve patient access, diversity, enrollment, and retention in clinical trials. Since their initial partnership in April 2021, they have worked on over 15 trials targeting 21,000 patients. The companies emphasize the growing demand for decentralized clinical trials, highlighting their commitment to technology-driven solutions for better patient engagement and outcomes.

Syneos Health (Nasdaq:SYNH) recently unveiled its 2023 Health Trends, highlighting how AI and machine learning are poised to revolutionize biopharmaceutical product development. The report identifies key trends anticipated to shape the industry, including advances in data utilization, increased focus on equitable representation in clinical trials, and a renewed commitment to mental health for healthcare professionals. The organization emphasizes 2023 as a pivotal year for innovation, driven by technological advancements and a need for improved medical affairs.

Syneos Health (Nasdaq:SYNH) announced that CEO Michelle Keefe will participate in a fireside chat at the 2022 Evercore ISI HealthCONx Conference on December 1, 2022, at 7:00 a.m. ET. The company will not hold investor meetings during this event. A live webcast will be available on the company's Investor Relations website, along with an archived replay link.

As a fully integrated biopharmaceutical solutions organization, Syneos Health accelerates customer success by strategically integrating clinical development, medical affairs, and commercial capabilities.

Syneos Health reported third-quarter revenue of $1,336.2 million, reflecting a 0.9% decrease year-over-year, though it increased 2.2% on a constant currency basis. Clinical Solutions saw a significant decline in new business awards, with a book-to-bill ratio of 0.18x, down 86.5% year-over-year. GAAP net income rose 11.3% to $87.0 million, resulting in diluted EPS of $0.84. Full-year 2022 guidance has been updated to project revenue between $5.3 billion and $5.36 billion. The company aims to enhance performance through strategic initiatives following disappointing results.

Syneos Health (Nasdaq:SYNH) has launched a dedicated HUB Patient Suite aimed at optimizing prescription management and improving patient adherence. This solution integrates advisory, analytics, and digital capabilities to enhance the patient experience from prescription to therapy adherence. With a focus on data-driven decision-making, the HUB will streamline communications between patients, providers, and biopharma companies. The initiative includes an exclusive partnership with Phil Inc. to modernize patient access to medications, ensuring patients receive necessary therapies effectively.